Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Insights into the DREAMM-14 trial

Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the DREAMM-14 trial (NCT05064358), which is evaluating different dosing regimens of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM), with the main aim of minimizing the ocular toxicity associated with this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research Funding: GSK, Amgen, Daiichi Sankyo, Cosette
Advisory board: BMS
Consultancy: Curio Science LLC, Intellisphere LLC
Membership on an entity’s Board of Directors or advisory committees: GSK